GAL and head and neck squamous cell carcinoma: Likewise, Gal and GalR1/2 promoter methylation status may serve as a potential biomarker for predicting clinical outcomes in patients with HN SCCs and salivary duct carcinoma, a rare and aggressive parotid gland malignancy (166, 168).